Citizen Petitions: FDA Will Speed Reviews Via Centralization, Not Decoupling
Executive Summary
FDA is taking several administrative steps toward streamlining its review of citizen petitions, including designating staff to concentrate on the submissions
You may also be interested in...
ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources
FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said
ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources
FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said
FDA Will Refer Potentially Anti-Competitive Citizen Petitions To FTC
Questionable citizen petitions will be referred to the Federal Trade Commission, FDA says in a report made to House and Senate appropriations committees